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fractions against 69.1 Gy/32 fractions in the IMRT group. 
Endpoints were local control, acute and late toxicity.  
Results A. Interim analysis (n = 150) showed low rates of 
moist desquamation, mostly located in the infra-mammary 
fold (5/75 WBI-SeqB vs 3/75 WBI-TDP-SIB, p =0.5). Trends in 
favor of WBI-TDP-SIB were observed for breast edema 
(p=0.08) and pruritus (p = 0.1). B. The volume of normal 
tissue receiving 4 Gy, 6 Gy and 8 Gy was at least 3, 6 and 13 
times smaller in the DP-8Gy arm compared to Conv-8Gy and 
DP-16Gy (p<0.05). DP-8Gy resulted in a pain response of 80% 
compared to 53% and 60% for Conv-8Gy and DP-16Gy. Quality 
of life analysis suggests better outcome for patients treated 
in the DP-8Gy arm with the scores ‘painful characteristic’, 
‘insomnia’ and ‘appetite loss’ reaching significance (p<0.05). 
C. Local control at 5 y was 83.4% and 75.2% in the DP- and 
IMRT-treated patients, respectively (p=0.28). Grades of acute 
dysphagia and mucositis were higher for the DP- than for the 
IMRT-treated group (p=0.03 and p=0.08, respectively) but 
differed according to DP-technique and –prescription. Poorly 
healing mucosal ulcers at the locations of the highest doses 
were observed in 9 DP- and 3 IMRT-treated patients (p=0.07) 
and reflect dose-limiting toxicity (DLT). Analysis of all DP-
treated patients showed that DP-planning using a linear 
relation between 18F-FDG voxel-intensity and dose was 
associated with high risk of DLT if peak-doses were >84 Gy or 
the volume receiving >80 Gy was >1.75 cc in 30-fraction 
schedules (OTT = 6 weeks). Discussion and conclusions  
The term DP covers a variety of techniques that open a vast 
spectrum of applications.The use of TDP after breast-
conserving surgery allows to integrate boost treatment in WBI 
without increasing toxicity. In bone metastasis, DP-8Gy was 
selected as a candidate experimental arm to test the 
hypothesis of improved palliation by reducing the irradiated 
volume. A confirmatory phase III trial is underway. In loco-
regionally advanced head&neck cancer, DP may open a 
window for improving local control. However, the safety 
margin for dose-escalation is narrow. Poorly healing mucosal 
ulcers at the peak-dose regions are DLT of DP. The 
dose/volume/DLT relationship casts doubt on the safety of 
linear 18F-FDG voxel-intensity based DP. A phase III trial 
using non-linear DP is underway. Tumor heterogeneity –
known for decades- supports DP and refutes the use of 
homogeneous dose distributions. Dose escalation to 
radioresistant regions in the tumor or decreasing the 
irradiated volume may be a conceptually naive way to use 
DP. The insight that ionizing radiation can enhance vascular 
and immunogenic mechanisms of cell death opens a new field 
for DP characterized by large fraction doses to small sub-
volumes of tumor. In these applications, direct cancer cell 
kill might be subordinate to other goals of DP including 
amplifying bystander and abscopal effects or breaking 
immune tolerance. Combination of DP with 
immunomodulating drugs or drugs that target vasculature or 
immune checkpoints are investigated to validate these 
concepts. 
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Any additional dose that can be applied without harm will lift 
tumour control in a patient population. Dose painting (DP) 
claims to make better use of dose than an indiscriminate or 
random escalation: by virtue of functional imaging, it should 
be more effective, more selective and more patient-specific. 
Still, on a pragmatic level, DP can often be summarized by 
“we boost because we can”. What does it take to go more 
biological?  
Obstacles lie in quantitative functional image acquisition, 
image interpretation, dose prescription and collection of 
evidence. Unfortunately, quantitative functional imaging is 
notoriously capricious. The problems tend to grow the more 
specific in terms of tumour biology an imaging modality is - 
which is one of the reasons for the popularity of FDG-PET, 
being arguably one of the least specific modalities. A specific 
modality may be more intriguing scientifically, but obviously 
shows only a narrow aspect of tumour biology, which may 
create a need for a combination of multiple modalities. 
Imaging modalities usually operate at length scales far 
greater than the phenomena to which they are sensitive. This 
can make the interpretation of images challenging, especially 
when tracer kinetics need to be considered. Imaging 
sophistication alone reveals little of the import of some 
physiological or biological trait for treatment outcome. Only 
clinical data can fill this gap in biological understanding with 
some confidence. Further, a single image is just a snapshot of 
a dynamically evolving tumour, and if taken pre-treatment, 
says little about the tumour´s response to therapy. 
Therefore, without any highly suggestive clinical evidence, 
the prospects for naive (i.e. model-based) DP are bleak.  
Accordingly, the majority of DP trials to date are pragmatic 
in their choice of imaging modality and –protocol, and dose 
prescription. In addition to being practical, especially in a 
multi-centric setting, this also ensures that a proof of benefit 
(of both boosting and imaging) can eventually be made. The 
essential advantage of “we boost because we can” over 
sophisticated “dose painting by numbers” is, that it 
generates the data needed to reach said sophistication.  
From this pragmatic standpoint, neither today´s imaging 
capabilities nor the understanding of their relevance to 
tumour treatment response are sufficient to speak of an 
established biological rationale for DP. Some clinical 
evidence exists in few instances that links certain functional 
imaging to lack of tumour control or even location of 
recurrence. Given this, workable DP concepts today are 
rather shaped by considerations about image sensitivity and 
specificity and organ mobility, than biology. 
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Purpose/Objectives: This work aims at formally identifying 
the methodological issues that hinder the implementation 
and adoption of dose painting (DP) in radiotherapy. DP entails 
the use of functional imaging to set up a non-uniform dose 
escalation, either with sub-contours or voxel-to-voxel 
variations. Although theoretically appealing, DP has not 
succeeded yet in passing from research to clinical use. This 
work reviews the physical, mathematical, and statistical 
causes of this delay, in the specific case of DP guided by PET.  
 
Method: The following steps occur in PET-based DP: 
acquisition of PET images (before and/or during treatment, 
with one or several tracers), conversion of the uptake(s) into 
a dose increment, treatment plan optimization, fractionated 
treatment delivery, accumulation and assessment of the 
delivered dose, and optional treatment adaptation. Every 
step or piece of data in this path can be modeled to 
investigate its shortcomings. All PET tracers are 
characterized with their specificity and sensitivity as a 
surrogate of some biological variable of interest in given 
conditions (e.g., before or during radiotherapy). PET images 
are described by their resolution and signal-to-noise ratio. 
Treatment plan quality is assessed by a quality-volume 
histogram (QVH), namely, a DP-specific dose-volume 
histogram that considers the ratio planned dose over 
prescribed dose. Random and systematic patient setup errors 
are quantified with their respective standard deviation. Non-
rigid registration of pre- and per-treatment images is used to 
approximate the cumulated dose, taking into account patient 
evolution (tumor regression, possible weight loss).  
 
Results: Our main result is the formal proof that PET-based 
DP cannot lead to a delivered dose that is strongly correlated 
with the tracer uptake at the microscopic level. This weak 
correlation is caused by: i) The limited information conveyed 
by heterogeneities observed in PET images. Current PET 
systems have a low resolution and a low signal-to-noise ratio, 
